Skip to content

The American Cancer Society & Flatiron Health Announce Recipients of Third Annual Real-World Data Impact Award


October 2022

The American Cancer Society & Flatiron Health Announce Recipients of Third Annual Real-World Data Impact Award

Grantees will receive funding and data to research inequities among treatments for patients with advanced cancers and their related outcomes


The American Cancer Society (ACS) and Flatiron Health announced today that the 2022 Real-World Data Impact Awards will support clinically-relevant research with a focus on health inequities among treatment for patients with advanced cancers and their related outcomes.

This year marks the third year of the joint grant-making program, under which ACS-funded researchers have the opportunity to apply for additional funding and access to Flatiron real-world data.

Eligible applicants are ACS awardees experienced in health-services and observational research and are encouraged to submit proposals that address health inequities.

The 2022 grants have been awarded to:

  • Avonne Connor, PhD, Assistant Professor of Epidemiology and Oncology at Johns Hopkins Bloomberg School of Public Health (JHSPH) and Sidney Kimmel Cancer Center who will be conducting a real-world evaluation of racial disparities in risk of cardiac outcomes after breast cancer treatment

  • Caitlin Murphy, PhD, Associate Professor in the Department of Health Promotion and Behavioral Sciences at the School of Public Health at the University of Texas Health Science Center at Houston (UTHealth), who will be studying racial and ethnic disparities in treatment patterns among young adults with metastatic colorectal and breast cancer

  • Kali Zhou, MD, Assistant Professor of Clinical Medicine at the University of California, San Francisco (UCSF) who will be investigating the potential of using real-world data to inform present-day treatment decision making for patients with hepatocellular carcinoma.

“Flatiron Health is thrilled to continue our partnership with ACS as we recognize the impact of real-world data to accelerate innovative and solution-oriented cancer health equity research that improves patient lives,” said Rebecca Miksad, MD, MPH, senior medical director at Flatiron Health. “Real-world data has multidimensional richness that will allow cancer research to be more representative and inclusive of all patients.”

“The American Cancer Society is excited to continue our partnership with Flatiron Health to fund research using their real-world data,” said Elvan C Daniels, Md. MPH, Senior Vice President, Extramural Discover Science at the American Cancer Society. “This unique data source allows investigators to answer important, timely research questions using data collected as care is being delivered.”

The 2022 Real-World Data Impact Award grantees will each receive $75,000 and access to a Flatiron de-identified dataset derived from the health records of patients with cancer treated in both community clinics and academic medical centers specific to their research questions. Additionally, awardees will have access to Flatiron and ACS clinical and methodological experts.

The joint grant-making program supports Flatiron’s and ACS’ goals of accelerating cancer research and improving treatment and outcomes for patients.

About the American Cancer Society

The American Cancer Society is the leading cancer-fighting organization with a vision to end cancer as we know it for everyone. For more than 100 years, we have been the only organization improving the lives of people with cancer and their families through advocacy, research, and patient support, to ensure that everyone has an opportunity to prevent, detect, treat, and survive cancer. To learn more, visit or call our 24/7 helpline at 1-800-227-2345. Connect with us on FacebookTwitter, and Instagram.

About Flatiron Health

Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.

Media Contacts

Anne Reynolds-Doerr

Flatiron Health:
Nina Toor